Keywords: Novartis, Serelaxin, Relaxin, RLX030, Acute heart failure, AHF

Novartis' serelaxin reduces mortality in AHF patients

Article | 25 September 2012

Print This

Phase III study results released by Swiss drug major Novartis (NOVN: VX) yesterday show that its investigational drug RLX030 (serelaxin; ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in